Treatment options for HCC patients who are not eligible for or progressed on IO. Clinical considerations and when to switch

Tuesday, 23rd May, 2023
11:00h - 13:30h (UTC)

Prof. Michel Ducreux

Head of GI Oncology

Department of Medical Oncology, Gustave Roussy France

France

More information

Dr. Timon Vandamme

Medical Oncologist

Digestive and Neuroendocrine Oncology, University Hospital Antwerp, Belgium

Belgium

More information

Assoc. Prof. Changhoon Yoo

Medical Oncologist

Department of Oncology, ASAN Medical Center, Seoul, South Korea

South Korea

More information

A virtual Experts Knowledge Share on the topic ‘Treatment options for HCC patients who are not eligible for or progressed on IO. Clinical considerations and when to switch’, chaired by Prof Michel Ducreux (France) and co-chaired by Dr Timon Vandamme (Belgium) and Assoc. Prof. Changhoon Yoo (South Korea).

Learn about and discuss:
1) The outcomes of patients with HCC receiving 1st line immunotherapy. When is the right time to switch?
2) The treatment options for patients with advanced HCC who are not eligible for IO in first line.
3) The data supporting 2nd line treatment options in advanced HCC. How to achieve optimal sequencing?

This event is in collaboration with HCC CONNECT, a group of international experts in liver oncology.

You will also have the opportunity to contribute to the discussion on this important topic in HCC. If you would like to submit a question for the Scientific Committee, please send them to Selina.gill@cor2ed.com